• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Medulloblastoma - Pipeline Review, H1 2012 Product Image

Medulloblastoma - Pipeline Review, H1 2012

  • ID: 2021882
  • January 2012
  • 87 pages
  • Global Markets Direct

Medulloblastoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Medulloblastoma - Pipeline Review, H1 2012', provides an overview of the Medulloblastoma therapeutic pipeline. This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medulloblastoma. 'Medulloblastoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Medulloblastoma.
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Medulloblastoma Overview
Therapeutics Development
An Overview of Pipeline Products for Medulloblastoma
Medulloblastoma Therapeutics under Development by Companies
Medulloblastoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Medulloblastoma Therapeutics – Products under Development by Companies
Medulloblastoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Medulloblastoma Therapeutics Development
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Archer Biosciences, Inc
Medulloblastoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Zactima + Isotretinoin - Drug Profile
Alimta - Drug Profile
Gemcitabine + Oxaliplatin - Drug Profile
GW572016 - Drug Profile
LDE225 - Drug Profile
Irinotecan + Temozolomide - Drug Profile
Bevacizumab + Camptosar - Drug Profile
Torisel - Drug Profile
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile
Etoposide + Filgrastim + Cisplatin + Cyclophosphamide + Vincristine sulfate + Radiation Therapy - Drug Profile
Cisplatin + Cyclophosphamide + Etoposide + Lomustine + Vincristine + Radiation Therapy - Drug Profile
Verteporfin - Drug Profile
Carboplatin + Cisplatin - Drug Profile
LEQ506 - Drug Profile
Dendritic cells + Imiquimod - Drug Profile
Cyclophosphamide + Etoposide + Cisplatin + Vincristine + Thiotepa + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile
Cyclophosphamide + Vincristine Sulfate - Drug Profile
Cisplatin + Lomustine + Vincristine Sulfate - Drug Profile
ARC-100 + Temodar - Drug Profile
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile
ABT-888 + Temozolomide - Drug Profile
Irinotecan + Temozolomide - Drug Profile
Isotretinoin + Vorinostat - Drug Profile
Isotretinoin + Vorinostat - Drug Profile
Tipifarnib - Drug Profile
Temozolomide + Irinotecan + Bevacizumab - Drug Profile
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile
Nifurtimox + Cyclophosphamide + Topotecan - Drug Profile
Temozolomide + Etoposide - Drug Profile
TTRNA-xALT + TTRNA-DCs - Drug Profile
Siomycin A - Drug Profile
Medulloblastoma Therapeutics – Drug Profile Updates
Medulloblastoma Therapeutics - Dormant Products
Medulloblastoma – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Medulloblastoma, H1 2012
Products under Development for Medulloblastoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Eli Lilly and Company, H1 2012
Novartis AG, H1 2012
Pfizer Inc., H1 2012
Archer Biosciences, Inc, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Medulloblastoma Therapeutics – Drug Profile Updates
Medulloblastoma Therapeutics – Dormant Products
Medulloblastoma Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Medulloblastoma, H1 2012
Products under Development for Medulloblastoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos